PeptideSearch

Argireline

Tested in people

Get notified when the evidence changes.

It has been tested in people, but it is not an approved medicine. The studies are usually small.

Compiled and reviewed by the PeptideSearch Editorial Team · Status checked 2026-08-04

Also called Acetyl Hexapeptide-8 / Acetyl Hexapeptide-3 / AH8

A skincare ingredient marketed as a topical alternative to Botox. Sold in cosmetics, not prescribed.

Official status: Not nominated for 503A compounding · Checked 2026-08-04

Can a doctor prescribe this?

Small pharmacy (503A)
Never put forward to FDA
Large outsourcing facility (503B)
Category 3 — not enough evidence sent in

Sold as a cosmetic ingredient, which is regulated differently from drugs.

503A is a pharmacy making a single prescription for one patient. 503B is a facility making batches. They are governed by separate lists. Where a category is shown, it is a position on the FDA's list of substances that have been put forward and are still being worked through — not the final list, which is set by rulemaking. Category 1 means the FDA does not plan to act against a pharmacy that makes it while the review runs.

Lab suppliers we list: 3

Doses used in research

Taken word for word from the studies and trials listed on this page. This is not a recommendation and not a dose for anyone to take.

No dosing information has been published in the research indexed here.

Spot an error? corrections@peptidesearch.org

What has happened so far

  1. 21 March 2025503B

    FDA lists "Argireline" under 503B Category 3: Bulk Drug Substances Nominated Without Adequate Support — someone put it forward, but what was sent in did not include enough evidence for the FDA to judge it. Read from the FDA 503B category document dated March 21, 2025.

    FDA

We'll email you when a new study, trial or status change lands for Argireline. Unsubscribe in one click.